

Seletracetam lithium

Cat. No.:	HY-119810A
Molecular Formula:	$C_{10}H_{14}F_2LiN_2O_2$
Molecular Weight:	239.17
Target:	HIV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Seletracetam (Ucb 44212) lithium, as an analog of the antiepileptic agent Levetiracetam, is a SV2A modulator for the research of epilepsy ^{[1][2][3]} .
IC ₅₀ & Target	SV2A ^[1]
In Vitro	<p>Seletracetam lithium decreases seizure activity in a number of epilepsy models and binds to the synaptic vesicle protein SV2A^[2].</p> <p>Seletracetam lithium decreases synaptic responses in a time-, frequency- and concentration-dependent manner^[2].</p> <p>Seletracetam lithium modifies rates of presynaptic release^[2].</p> <p>Seletracetam lithium inhibits high-voltage-activated Ca²⁺ currents and intracellular Ca²⁺ increase in rat cortical neurons in vitro^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

- [1]. Pollard JR, et al. Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy. *Curr Opin Investig Drugs*. 2008 Jan;9(1):101-7.
- [2]. Yang X, et al. Seletracetam enhances short term depression in vitro. *Epilepsy Res*. 2015 Nov;117:17-22.
- [3]. Martella G, et al. Seletracetam (ucb 44212) inhibits high-voltage-activated Ca²⁺ currents and intracellular Ca²⁺ increase in rat cortical neurons in vitro. *Epilepsia*. 2009 Apr;50(4):702-10.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA